Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-pid study: Quality of life with switch from 5-day therapy to patient-initiated famciclovir in recurrent herpes simplex
jRCT1031210377Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of famciclovir in herpes simplex (HSV), sponsored by Maruho Co., Ltd. Primary endpoints: QOL at recurrence under 5-day therapy, QOL at recurrence under patient-initiated therapy (PIT) and 2 more. Started Oct 2021; status: completed.
02
Drugs
famciclovir
03
Conditions
herpes simplex (HSV)
Beyond the preview
Go deeper on jRCT1031210377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210377.